Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

miRNA-mediated targeting of human cytomegalovirus reveals biological host and viral targets of IE2.

Møller R, Schwarz TM, Noriega VM, Panis M, Sachs D, Tortorella D, tenOever BR.

Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):1069-1074. doi: 10.1073/pnas.1719036115. Epub 2018 Jan 16.

2.

Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity.

Bardina SV, Bunduc P, Tripathi S, Duehr J, Frere JJ, Brown JA, Nachbagauer R, Foster GA, Krysztof D, Tortorella D, Stramer SL, García-Sastre A, Krammer F, Lim JK.

Science. 2017 Apr 14;356(6334):175-180. doi: 10.1126/science.aal4365. Epub 2017 Mar 30.

3.

Functional screening for anti-CMV biologics identifies a broadly neutralizing epitope of an essential envelope protein.

Gardner TJ, Stein KR, Duty JA, Schwarz TM, Noriega VM, Kraus T, Moran TM, Tortorella D.

Nat Commun. 2016 Dec 14;7:13627. doi: 10.1038/ncomms13627.

4.

The Microtubule Inhibitor Podofilox Inhibits an Early Entry Step of Human Cytomegalovirus.

Cohen T, Schwarz TM, Vigant F, Gardner TJ, Hernandez RE, Lee B, Tortorella D.

Viruses. 2016 Oct 24;8(10). pii: E295.

5.

Rescue of the 1947 Zika Virus Prototype Strain with a Cytomegalovirus Promoter-Driven cDNA Clone.

Schwarz MC, Sourisseau M, Espino MM, Gray ES, Chambers MT, Tortorella D, Evans MJ.

mSphere. 2016 Sep 28;1(5). pii: e00246-16. eCollection 2016 Sep-Oct.

6.

Convallatoxin-Induced Reduction of Methionine Import Effectively Inhibits Human Cytomegalovirus Infection and Replication.

Cohen T, Williams JD, Opperman TJ, Sanchez R, Lurain NS, Tortorella D.

J Virol. 2016 Nov 14;90(23):10715-10727. doi: 10.1128/JVI.01050-16. Print 2016 Dec 1.

7.

Virion Glycoprotein-Mediated Immune Evasion by Human Cytomegalovirus: a Sticky Virus Makes a Slick Getaway.

Gardner TJ, Tortorella D.

Microbiol Mol Biol Rev. 2016 Jun 15;80(3):663-77. doi: 10.1128/MMBR.00018-16. Print 2016 Sep. Review.

8.

ISG15 deficiency and increased viral resistance in humans but not mice.

Speer SD, Li Z, Buta S, Payelle-Brogard B, Qian L, Vigant F, Rubino E, Gardner TJ, Wedeking T, Hermann M, Duehr J, Sanal O, Tezcan I, Mansouri N, Tabarsi P, Mansouri D, Francois-Newton V, Daussy CF, Rodriguez MR, Lenschow DJ, Freiberg AN, Tortorella D, Piehler J, Lee B, García-Sastre A, Pellegrini S, Bogunovic D.

Nat Commun. 2016 May 19;7:11496. doi: 10.1038/ncomms11496.

9.

Human cytomegalovirus gH stability and trafficking are regulated by ER-associated degradation and transmembrane architecture.

Gardner TJ, Hernandez RE, Noriega VM, Tortorella D.

Sci Rep. 2016 Mar 30;6:23692. doi: 10.1038/srep23692.

10.

Combating Frosting with Joule-Heated Liquid-Infused Superhydrophobic Coatings.

Elsharkawy M, Tortorella D, Kapatral S, Megaridis CM.

Langmuir. 2016 May 3;32(17):4278-88. doi: 10.1021/acs.langmuir.6b00064. Epub 2016 Apr 22.

11.

Targeting Viral Proteostasis Limits Influenza Virus, HIV, and Dengue Virus Infection.

Heaton NS, Moshkina N, Fenouil R, Gardner TJ, Aguirre S, Shah PS, Zhao N, Manganaro L, Hultquist JF, Noel J, Sachs D, Hamilton J, Leon PE, Chawdury A, Tripathi S, Melegari C, Campisi L, Hai R, Metreveli G, Gamarnik AV, García-Sastre A, Greenbaum B, Simon V, Fernandez-Sesma A, Krogan NJ, Mulder LCF, van Bakel H, Tortorella D, Taunton J, Palese P, Marazzi I.

Immunity. 2016 Jan 19;44(1):46-58. doi: 10.1016/j.immuni.2015.12.017. Erratum in: Immunity. 2016 Feb 16;44(2):438. Sachs, David H [corrected to Sachs, David].

12.

Development of a high-content screen for the identification of inhibitors directed against the early steps of the cytomegalovirus infectious cycle.

Gardner TJ, Cohen T, Redmann V, Lau Z, Felsenfeld D, Tortorella D.

Antiviral Res. 2015 Jan;113:49-61. doi: 10.1016/j.antiviral.2014.10.011. Epub 2014 Oct 31.

13.

Human cytomegalovirus modulates monocyte-mediated innate immune responses during short-term experimental latency in vitro.

Noriega VM, Haye KK, Kraus TA, Kowalsky SR, Ge Y, Moran TM, Tortorella D.

J Virol. 2014 Aug;88(16):9391-405. doi: 10.1128/JVI.00934-14. Epub 2014 Jun 11.

14.

Human cytomegalovirus US28 facilitates cell-to-cell viral dissemination.

Noriega VM, Gardner TJ, Redmann V, Bongers G, Lira SA, Tortorella D.

Viruses. 2014 Mar 12;6(3):1202-18. doi: 10.3390/v6031202.

15.

Novel class of potential therapeutics that target ricin retrograde translocation.

Redmann V, Gardner T, Lau Z, Morohashi K, Felsenfeld D, Tortorella D.

Toxins (Basel). 2013 Dec 23;6(1):33-53. doi: 10.3390/toxins6010033.

16.

Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis.

Miller MS, Gardner TJ, Krammer F, Aguado LC, Tortorella D, Basler CF, Palese P.

Sci Transl Med. 2013 Aug 14;5(198):198ra107. doi: 10.1126/scitranslmed.3006637.

17.

Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies.

Gardner TJ, Bolovan-Fritts C, Teng MW, Redmann V, Kraus TA, Sperling R, Moran T, Britt W, Weinberger LS, Tortorella D.

Clin Vaccine Immunol. 2013 Apr;20(4):540-50. doi: 10.1128/CVI.00644-12. Epub 2013 Feb 6.

18.

Human cytomegalovirus US3 modulates destruction of MHC class I molecules.

Noriega VM, Hesse J, Gardner TJ, Besold K, Plachter B, Tortorella D.

Mol Immunol. 2012 Jun;51(2):245-53. doi: 10.1016/j.molimm.2012.03.024. Epub 2012 Apr 10.

19.

Diverse immune evasion strategies by human cytomegalovirus.

Noriega V, Redmann V, Gardner T, Tortorella D.

Immunol Res. 2012 Dec;54(1-3):140-51. doi: 10.1007/s12026-012-8304-8. Review.

PMID:
22454101
20.

Dislocation of ricin toxin A chains in human cells utilizes selective cellular factors.

Redmann V, Oresic K, Tortorella LL, Cook JP, Lord M, Tortorella D.

J Biol Chem. 2011 Jun 17;286(24):21231-8. doi: 10.1074/jbc.M111.234708. Epub 2011 Apr 28.

21.

The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice.

Bongers G, Maussang D, Muniz LR, Noriega VM, Fraile-Ramos A, Barker N, Marchesi F, Thirunarayanan N, Vischer HF, Qin L, Mayer L, Harpaz N, Leurs R, Furtado GC, Clevers H, Tortorella D, Smit MJ, Lira SA.

J Clin Invest. 2010 Nov;120(11):3969-78. doi: 10.1172/JCI42563. Epub 2010 Oct 11.

22.

TRAM1 is involved in disposal of ER membrane degradation substrates.

Ng CL, Oresic K, Tortorella D.

Exp Cell Res. 2010 Aug 1;316(13):2113-22. doi: 10.1016/j.yexcr.2010.04.010. Epub 2010 Apr 27.

23.

TRAM1 participates in human cytomegalovirus US2- and US11-mediated dislocation of an endoplasmic reticulum membrane glycoprotein.

Oresic K, Ng CL, Tortorella D.

J Biol Chem. 2009 Feb 27;284(9):5905-14. doi: 10.1074/jbc.M807568200. Epub 2009 Jan 2.

24.

Human cytomegalovirus-encoded immune modulators partner to downregulate major histocompatibility complex class I molecules.

Noriega VM, Tortorella D.

J Virol. 2009 Feb;83(3):1359-67. doi: 10.1128/JVI.01324-08. Epub 2008 Nov 12.

25.

Cln6 mutants associated with neuronal ceroid lipofuscinosis are degraded in a proteasome-dependent manner.

Oresic K, Mueller B, Tortorella D.

Biosci Rep. 2009 Jun;29(3):173-81. doi: 10.1042/BSR20080143.

26.
27.

Cold neutron energy dependent production of ultracold neutrons in solid deuterium.

Atchison F, Blau B, Bodek K, van den Brandt B, Bryś T, Daum M, Fierlinger P, Frei A, Geltenbort P, Hautle P, Henneck R, Heule S, Holley A, Kasprzak M, Kirch K, Knecht A, Konter JA, Kuźniak M, Liu CY, Morris CL, Pichlmaier A, Plonka C, Pokotilovski Y, Saunders A, Shin Y, Tortorella D, Wohlmuther M, Young AR, Zejma J, Zsigmond G.

Phys Rev Lett. 2007 Dec 31;99(26):262502. Epub 2007 Dec 27. Erratum in: Phys Rev Lett. 2008 Oct 31;101(18):189902.

PMID:
18233572
28.
29.
30.

Signal peptide peptidase is required for dislocation from the endoplasmic reticulum.

Loureiro J, Lilley BN, Spooner E, Noriega V, Tortorella D, Ploegh HL.

Nature. 2006 Jun 15;441(7095):894-7. Epub 2006 May 31.

PMID:
16738546
31.

A structural determinant of human cytomegalovirus US2 dictates the down-regulation of class I major histocompatibility molecules.

Oresic K, Noriega V, Andrews L, Tortorella D.

J Biol Chem. 2006 Jul 14;281(28):19395-406. Epub 2006 May 10.

32.

Cotranslational endoplasmic reticulum assembly of FcepsilonRI controls the formation of functional IgE-binding receptors.

Fiebiger E, Tortorella D, Jouvin MH, Kinet JP, Ploegh HL.

J Exp Med. 2005 Jan 17;201(2):267-77. Epub 2005 Jan 10.

33.

Dissection of the dislocation pathway for type I membrane proteins with a new small molecule inhibitor, eeyarestatin.

Fiebiger E, Hirsch C, Vyas JM, Gordon E, Ploegh HL, Tortorella D.

Mol Biol Cell. 2004 Apr;15(4):1635-46. Epub 2004 Feb 6.

34.

A glycosylated type I membrane protein becomes cytosolic when peptide: N-glycanase is compromised.

Blom D, Hirsch C, Stern P, Tortorella D, Ploegh HL.

EMBO J. 2004 Feb 11;23(3):650-8. Epub 2004 Jan 29.

35.

Dislocation of a type I membrane protein requires interactions between membrane-spanning segments within the lipid bilayer.

Lilley BN, Tortorella D, Ploegh HL.

Mol Biol Cell. 2003 Sep;14(9):3690-8. Epub 2003 Jun 13.

36.

Ubiquitinylation of the cytosolic domain of a type I membrane protein is not required to initiate its dislocation from the endoplasmic reticulum.

Furman MH, Loureiro J, Ploegh HL, Tortorella D.

J Biol Chem. 2003 Sep 12;278(37):34804-11. Epub 2003 Jun 27.

37.

Protein unfolding is not a prerequisite for endoplasmic reticulum-to-cytosol dislocation.

Tirosh B, Furman MH, Tortorella D, Ploegh HL.

J Biol Chem. 2003 Feb 28;278(9):6664-72. Epub 2002 Dec 12.

38.
39.

Human cytomegalovirus gene products US2 and US11 differ in their ability to attack major histocompatibility class I heavy chains in dendritic cells.

Rehm A, Engelsberg A, Tortorella D, Körner IJ, Lehmann I, Ploegh HL, Höpken UE.

J Virol. 2002 May;76(10):5043-50.

40.

Visualization of the ER-to-cytosol dislocation reaction of a type I membrane protein.

Fiebiger E, Story C, Ploegh HL, Tortorella D.

EMBO J. 2002 Mar 1;21(5):1041-53.

41.

US2, a human cytomegalovirus-encoded type I membrane protein, contains a non-cleavable amino-terminal signal peptide.

Gewurz BE, Ploegh HL, Tortorella D.

J Biol Chem. 2002 Mar 29;277(13):11306-13. Epub 2002 Jan 14.

42.
43.

Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits.

Kessler BM, Tortorella D, Altun M, Kisselev AF, Fiebiger E, Hekking BG, Ploegh HL, Overkleeft HS.

Chem Biol. 2001 Sep;8(9):913-29.

44.

Virus subversion of immunity: a structural perspective.

Gewurz BE, Gaudet R, Tortorella D, Wang EW, Ploegh HL.

Curr Opin Immunol. 2001 Aug;13(4):442-50. Review.

PMID:
11498300
45.

Antigen presentation subverted: Structure of the human cytomegalovirus protein US2 bound to the class I molecule HLA-A2.

Gewurz BE, Gaudet R, Tortorella D, Wang EW, Ploegh HL, Wiley DC.

Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6794-9.

46.
47.

Signal peptide cleavage of a type I membrane protein, HCMV US11, is dependent on its membrane anchor.

Rehm A, Stern P, Ploegh HL, Tortorella D.

EMBO J. 2001 Apr 2;20(7):1573-82.

48.

Down-regulation of MHC class I antigen presentation by HCMV; lessons for tumor immunology.

Tortorella D, Gewurz B, Schust D, Furman M, Ploegh H.

Immunol Invest. 2000 May;29(2):97-100. Review. No abstract available.

PMID:
10854174
49.

Viral subversion of the immune system.

Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL.

Annu Rev Immunol. 2000;18:861-926. Review.

PMID:
10837078
50.

Viral immunoevasive strategies and trophoblast class I major histocompatibility complex antigens.

Schust DJ, Tortorella D, Ploegh HL.

J Reprod Immunol. 1999 Jul;43(2):243-51. Review. No abstract available.

PMID:
10479060

Supplemental Content

Loading ...
Support Center